740780-79-4

Basic information

• Product Name: (1R,3R)-Solifenacin Succinate 2
• Synonyms: (1R,3R)-Solifenacin Succinate 2
• CAS NO: 740780-79-4
• Molecular Formula: C₂₃H₂₆N₂O₂
• Molecular Weight: 362.46474
• Mol File: 740780-79-4.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 505.5±50.0 °C(Predicted)
• Appearance: /
• Density: 1.24±0.1 g/cm3(Predicted)
• PKA: 9.03±0.33(Predicted)
• CAS DataBase Reference: (1R,3R)-Solifenacin Succinate 2(CAS DataBase Reference)
• NIST Chemistry Reference: (1R,3R)-Solifenacin Succinate 2(740780-79-4)
• EPA Substance Registry System: (1R,3R)-Solifenacin Succinate 2(740780-79-4)

Safety Data

• Hazardous Substances Data: 740780-79-4(Hazardous Substances Data)

Usage

General Description

(1R,3R)-Solifenacin Succinate 2 is a chemical compound that belongs to the class of quinuclidines and is used as a medication to treat overactive bladder. It works by relaxing the muscles in the bladder, thereby reducing the urge to urinate frequently. This chemical is typically administered orally in the form of a tablet and is readily absorbed into the bloodstream. It is metabolized in the liver and excreted in the urine, with a half-life of around 65 hours. Common side effects of (1R,3R)-Solifenacin Succinate 2 include dry mouth, constipation, and difficulty urinating, although these effects are generally mild and well-tolerated by most patients.

Upstream product

• 180272-45-1 (R)-(-)-1-phenyl-1,2,3,4-tetrahydroisoquinoline 
• 25333-42-0 (R)-quinuclidin-3-ol 
• 1619-34-7 3-quinuclidinol 
• 22990-19-8 1-phenyl-1,2,3,4-tetrahydroisoquinoline 
• 180468-42-2 (S)-N-carboxylic acid ethyl ester-1-phenyl-1,2,3,4-tetrahydroisoquinoline 
• 180468-41-1 ethyl (R)-1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 180272-14-4 (S,R)-((R)-quinuclidin-3-yl) 1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 552831-23-9 (R)-imidazole-1-carboxylic acid 1-azabicyclo[2.2.2]oct-3-yl ester 
• 6970-83-8 ethyl-N-(2-phenethyl)carbamate 
• 102422-37-7 N-(1H-imidazol-1-ylcarbonyl)-2-phenethylamine 
• 64-04-0 phenethylamine 
• 3278-14-6 N-phenethylbenzamide 
• 52250-50-7 1-phenyl-3,4-dihydroisoquinoline 

Downstream Products

• 865813-78-1 (-)-(3R)-quinuclidin-3-yl (1R)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate p-toluenesulfonate 
• 865813-82-7 (-)-(3R)-quinuclidin-3-yl (1R)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate (-)-(2S,3S)-tartrate 
• 865813-72-5 (-)-(3R)-quinuclidin-3-yl (1R)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate (-)-L-phenylalaninate 
• 865813-80-5 (-)-(3R)-quinuclidin-3-yl (1R)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate methanesulfonate 
• 865813-74-7 (-)-(3R)-quinuclidin-3-yl (1R)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate cyclohexanesulfamate 
• 865813-79-2 (-)-(3R)-quinuclidin-3-yl (1R)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate ethanesulfonate 
• 865813-84-9 (-)-(3R)-quinuclidin-3-yl (1R)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate (+)-(2S,3S)-di-O-(4-methylbenzoyl)tartrate 
• 865813-77-0 (-)-(3R)-quinuclidin-3-yl (1R)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate (+)-camphor-10-sulfonate 
• 865813-76-9 (-)-(3R)-quinuclidin-3-yl (1R)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate sebacate 
• 865813-83-8 (-)-(3R)-quinuclidin-3-yl (1R)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate (+)-(2S,3S)-di-O-benzoyltartrate 
• 865813-75-8 (-)-(3R)-quinuclidin-3-yl (1R)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate naphthalene-2-sulfonate 
• 1035547-81-9 (3R)-1-azabicyclo[2.2.2]oct-3-yl (1S)-3,4-dihydro-1-phenyl-2(1H)-isoquinoline carboxylate hydrogen L-tartrate 
• 862207-71-4 (1S)-3,4-dihydro-1-phenyl-2-(1H)-isoquinolinecarboxylic acid (3S)-1-azabicyclo[2.2.2]oct-3-yl ester succinate 
• 862207-70-3 (3R)-1-azabicyclo[2.2.2]oct-3-yl (1R)-3,4-dihydro-1-phenyl-2(1H)-isoquinoline carboxylate succinate 

Relevant articles and documents

PROCESS FOR THE PREPARATION OF SOLIFENACIN AND SALTS THEREOF

The invention provides a new process for the preparation of solifenacin or a pharmaceutically acceptable acid addition salt thereof, comprising reacting (R)- quinuclidin-3-yl phenethylcarbamate with benzaldehyde in the presence of an acid to obtain a diasteroisomeric mixture (S,R)-((R)-quinuclidin-3-yl) 1 -phenyl-3,4- dihydroisoquinoline-2(1 H)-carboxylate of formula (IV) which can be resolved and the solifenacin or a pharmaceutically acceptable acid addition salt thereof recovered. The invention also provides the new key intermediate (R)-quinuclidin-3-yl phenethylcarbamate involved in the process. Further the invention provides a method for the transformation of (R)-((R)-quinuclidin-3-yl) 1 -phenyl-3,4- dihydroisoquinoline-2(1 H)-carboxylate into a diasteroisomeric mixture (S,R)-((R)- quinuclidin-3-yl) 1 -phenyl-3,4-dihydroisoquinoline-2(1 H)-carboxylate.

PROCESS FOR PREPARING CHEMICALLY AND CHIRALLY PURE SOLIFENACIN BASE AND ITS SALTS

The present invention provides improved processes for preparing chemically and chirally pure Solifenacin base. The present invention also provides for a composition comprising of a salt of Solifenacin having at least 98 % purity. The present invention also disclose certain new salts of Solifenacin as well as well as new polymorphic forms of Solifenacin hydrochloride and Solifenacin oxalate, in pure form.

PROCESS FOR PREPARING SOLIFENACIN AND ITS SALTS

The present invention relates to solifenacin in solid form and a process for its preparation and to a process for the preparation of (1S)-1-Phenyl-1,2,3,4-tetrahydro-isoquinoline, a key intermediate in the synthesis of solifenacin and its salts.